MicroRNAs (miRNAs) are a group of small non-coding RNAs that range in length from 20 to 25 nucleotides. MicroRNAs are specific for multiple cellular functions, including cell generation, differentiation, multiplication, carcinogenesis, and apoptosis. Many researchers have recently reported that the aberrant expression of miRNAs in hepatic tissue was related to the pathogenesis of liver disease, including viral hepatitis, hepatocellular carcinoma, and fatty liver disease. Multiple studies have proposed that an analysis of circulating miRNAs may be useful for diagnosing etiologies or staging the progression of liver disease, as well as for therapeutic purposes, for example, nucleic acid therapy. This review summarizes and discusses recent advances in the knowledge of miRNAs for chronic liver diseases, with special interest in viral hepatitis, liver fibrosis, and biomarkers.
INTRODUCTION
MicroRNAs are non-coding RNAs that control gene expression by annealing to complementary target mRNAs. MicroRNAs form RNA-induced silencing complexes with their target mRNAs in the cytoplasm, which inhibits the transfer and translation of mRNA. This process is referred to as RNAi. The 5′ 6-8 nucleotides of miRNA, which form the "seed sequence", anneal to a complementary 3′-untranslated region of the target mRNA during RNAi, which prevents subsequent processes. The mRNAs that are controlled by miRNAs are referred to as target genes. Hundreds of possible miRNA target genes exist in the human genome, and miRNAs likely control up to 60% of human mRNAs. 1 Therefore, miRNAs and their target genes cooperatively control life processes. 2, 3 Collectively, miRNAs participate in complex regulatory networks and control gene expression in all biological processes, including cell development, immune responses, aging, and cell death. A total of 1881 precursors and 2588 mature human miRNAs are registered in miRbase version 21.0 (http://www.mirbase.org).
BASIS OF MIRNAS IN LIVER
MicroRNA expression patterns differ dramatically in internal organs. MicroRNA-122 comprises~70% of miRNAs in hepatic tissue. 4 The function of miR-122 in liver varies, but it plays a crucial role in the regulation of cholesterol and fatty acid metabolism. Liver-enriched transcription factors, including HNF6 and 4a, regulate miR-122 expression 5 and control cell proliferation and differentiation in hepatocyte and cholangiocyte lineages. 6 The molecular mechanism of steatosis was first revealed during gene expression profiling in miR-122 knockout mice, in which genes involved in lipid synthesis in the liver, including Agpat1 and Cidec, were overexpressed. 7, 8 Gatfield et al. 9 reported that miR-122 influenced circadian rhythm by controlling the expression of metabolic regulators of the PPAR family. MicroRNA-122 expression also affects liver inflammation. 10 Several studies revealed that the expression of miR-122 was reduced in experimental models and clinical samples of HCC and that the loss of miR-122 was associated with tumor invasiveness and cancer progression. 7, 8, 11, 12 MicroRNA-33, 13 miR-27, miR-378, 15 miR-34, 16 and miR-21 17 are also involved in liver metabolism.
Collectively, miRNAs are important mediators of metabolic stress during hypoxia, hyperglycemia, hypertriglyceridemia, hypercholesterolemia, and caloric restriction, 18 and miR-122 regulates metabolic stress through cationic amino acid transporter 1.
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MICRORNA IN VIRAL HEPATITIS AND THERAPY
Hepatitis C virus M ICRORNA-122 CONTROLS HCV replication, 20 and most studies of miR-122 in liver tissue were carried out in the context of HCV replication. The suppression of miR-122 controls HCV replication for the following reasons: (i) the binding site of miR-122 is downstream of the IRES, which controls the early stages of HCV replication; 21 (ii) miR-122 controls the isoprenoid biosynthesis pathway, which may regulate HCV replication; 22 and (iii) miR-122 recognizes the 5′-and 3′-untranslated regions in the HCV genome as target genes. 23 MicroRNA-122 forms an oligomeric complex in which one miR-122 molecule binds to the 5′-terminus of the HCV RNA with 3′-overhanging nucleotides, which masks the 5′-terminal sequences of the HCV genome. 24 This effect of miR-122 on HCV is unusual. MicroRNA-199a targets domain II of the HCV IRES, which inhibits HCV replication. 25 MicroRNA-196 and miR-448 recognize NS5A and the core, 26 respectively, to control replication, and let-7b recognizes domain IV of the IRES, NS5B 27 ( Fig. 1 ).
The expression of miR-130a is significantly higher in HCV-infected hepatocytes and liver biopsy specimens than in uninfected controls. MicroRNA-130a reduces the expression of interferon-induced transmembrane 1 to inhibit HCV replication. 28 Hepatic miRNA expression patterns in patients with CHC prior to therapy with pegylated interferon and ribavirin are consistent with therapeutic outcomes. The expression of eight miRNAs (miR-27b, miR-378, miR-422b, miR-34b, miR-145, miR-143, miR-652, and miR-18a) differed significantly between samples from sustained virological response and non-responder groups, and the accuracy of this distinction was 70.5%. 29 The expression of miRNAs is unique in HBV and HCV infections, and it is associated with liver disease progression. Seventeen miRNAs (miR-130a, miR-200a, miR-200b, miR-223, miR-326, miR-187, miR-199-s, miR-199a, miR-199a*, miR-125b, miR-17-3p, miR-92, miR-139, miR-122a, miR-30e, miR-30a-3p, and miR-99a) were downregulated in HCC cells, which led to the upregulation of cancer-associated pathways involved in the cell cycle, adhesion, proteolysis, transcription, and translation. Six miRNAs (miR-21, miR-98, miR-183, miR-301, miR-221, and miR-222) were upregulated in HCC, which downregulated the antitumor immune response (Table 1) . 30 Nucleic acid therapies recently emerged as potential strategies for the treatment of CHC, and these therapies showed high efficacy and few adverse effects. Treatment of locked nucleic acid-modified miRNAs, complementary to miR-122 (miravirsen), caused prolonged dose-dependent 
Hepatitis B virus
MicroRNAs are known regulators of HBV replication, and HBV-related proteins regulate miRNA expression. Multiple miRNAs affect HBV replication through epigenetic mechanisms and direct regulation of transcription factors. Other miRNAs recognize specific target genes in the HBV genome.
Endothelin 1 is significantly upregulated in HBxinduced HCC in mice. Endothelin 1 plays an important role in HCC progression through activation of the PI3K/AKT pathway, and it is regulated by miR-1. 32 Hepatitis B x protein downregulates let-7 expression in HepG2 cells 33 and upregulates signal transducer and activator of transcription 3. 34 MicroRNA-548p suppresses HBx through downregulation of oncoprotein HBx-interacting protein.
35 Downregulated miR-152 induces aberrant DNA methylation in HBV-related HCC through DNA methyltransferase 1. MicroRNA-15b, miR-18a, miR-122, miR-141, and miR-372 regulate HBV transcription factors to control replication. MicroRNA-15b directly downregulated HNF1α mRNA, which resulted in the transactivation of HBV enhancer I. 37 MicroRNA-18a suppressed the synthesis of estrogen receptor α and stimulated cell proliferation through expression of the estrogen receptor 1 gene. 38 MicroRNA-122 is a broad regulator of HBV replication, and it directly regulates N-myc downstream-regulated gene 3, which suppresses replication. 39 The HBV mRNAmediated inhibition of miR-122 causes the upregulation of PTTG1-binding protein, which promotes HCC tumor growth and cell invasion. 40 MicroRNA-141 represses HBV replication by targeting PPARA, 41 and miR-372/373 promotes HBV by targeting nuclear factor I/B.
42
The miR-15a/miR-16-1 cluster recognizes a region of overlap between HBV polymerase and HBx, 43 and miR-122 recognizes the polymerase region across multiple HBV subtypes. 44 The HBV polymerase overlap region is also a target for miR-125a-5p and miR-199a-3p. 45 The HBV preS1 region is a target of miR-210 46 ( Fig. 2) , and miR-1231 suppresses HBV replication by targeting the core mRNA (Table 2 ). 47 A current clinical trial is evaluating an RNAi-based drug that recognizes the 3′-end of gene X. The siRNA ARC-520 is a dynamic polyconjugate in which the RNAi trigger is conjugated to cholesterol. The conjugate is coinjected with a hepatocyte-targeted, membrane-active peptide. Phase IIa of the clinical trial revealed that the drug was well tolerated and caused a significant dosedependent reduction in hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B. 48 This drug candidate is not based on miRNA, but it relies on a similar technology. 
MICRORNA IN LIVER FIBROSIS
Pathophysiology of liver fibrosis L IVER FIBROSIS IS a pathological manifestation of chronic liver disease (CLD) caused by any etiology, including HCV or HBV infection, alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, and biliary cholangitis. Extracellular matrix materials replace the hepatic parenchyma in liver fibrosis. Fibrotic septum is composed of HSCs, myofibroblasts, vasculature, and inflammatory cells, but HSCs are the most important cells for the production of extracellular matrix materials and pro-fibrogenic mediators. Hepatic stellate cells become activated following chronic liver trauma and transdifferentiate to myofibroblast-like cells, which are characterized by a lower amount of vitamin A, abundant expression of α-SMA and growth factor receptors, and incremental production of collagens. The following factors initiate HSC activation: (i) damage-associated molecular patterns, that is, the chromatin-associated protein highmobility group box 1, DNA and RNA, S100 molecules, and reactive oxygen species derived from damaged hepatocytes; (ii) paracrine production of stimuli, such as reactive oxygen species, cytokines, platelet-derived growth factor, TGF-β, and monocyte chemotactic protein-1 by sinusoidal endothelial cells, Kupffer cells, and cholangiocytes; and (iii) signal molecules from platelets and the immune system. Activated HSCs secrete an increased amount of MMPs and their inhibitors, TIMPs.
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Activation of HSCs is strictly controlled by transcription factors, such as activated protein-1, Jun D, Sp1, Kruppellike factor 6, and NF-κB, under the control of Smad, Ras, Raf-1, and mitogen-activated protein kinase. Hypermethylation of PTEN occurs in activated HSCs. Activation of extracellular signal-regulated kinase and AKT is restricted by PTEN, and repression of PTEN in activated 
MicroRNA-21
MicroRNA-21 is an "onco-miR", and it is frequently overexpressed in solid tumors. The human MIR21 gene is localized on the plus strand of chromosome 17q23.2, and it is transcriptionally upregulated by NF-κB. MicroRNA-21 is upregulated in liver fibrosis in human CLD and experimentally induced rodent models. Zhang et al. reported that upregulated miR-21 expression in activated HSCs is maintained through a feedback loop that consists of miR-21, programmed cell death protein 4, and activation protein-1, and it promotes the TGF-β signaling pathway. 55 He et al. showed that recombinant adenoassociated virus serotype 8-mediated downregulation of miR-21 protected mice with a lethal infection of Schistosoma japonica through attenuation of the progression of liver fibrosis and hepatocyte damage. They also confirmed the involvement of IL-13 in addition to TGF-β in miR-21 induction for activated HSCs. 56 MicroRNA-21 is also involved in ethanol-induced liver injury and HSC activation mediated by IL-6/Stat3 and targets Fas ligand (TNF superfamily, member 6) and death receptor 5. 57 
MicroRNA-29
The miR-29 group is composed of miR-29a, 29b, and 29c, in which the former two miRNAs are processed from chromosome 7 and the latter two are transcribed from chromosome 1. MicroRNA-29 generally targets myeloid leukemia cell differentiation protein, DNA methyltransferases DNMT3A and DNMT3B, and zinc finger protein 36 homolog. MicroRNA-29 may also play an antifibrotic role in the liver and other organs. Roderburg et al. and our group previously reported that miR-29 was downregulated in rodent models of liver fibrosis induced by CCl 4 or bileduct ligation and human cirrhotic livers and that miR-29 expression decreased dependently to HSC activation in primary culture. 58, 59 Forced overexpression of miR-29 showed marked suppression of collagen 1 A1 mRNA and protein expression and attenuated HSC activation, which indicates an anti-fibrotic action of miR-29 in the liver. The downregulation of the expression of heat shock protein 47 and lysyl oxidase is involved in the inhibition of collagen maturation by miR-29b. 60 A single systemic delivery of miR-29a expressing adeno-associated virus prevented and reversed fibrosis development in CCl 4 -treated mice. 61 MicroRNA-29b caused cell cycle arrest in the G 1 phase through reduction of cyclin D1 levels and induced HSC apoptosis by inhibition of the PI3K/AKT pathway. The antifibrotic action of hepatocyte growth factor and class II histone deacetylase inhibitor may be mediated by the induction of miR-29. 
MicroRNA-222
MicroRNA-222 and its paralogue miR-221 are onco-miRs and regulators of angiogenesis. MicroRNA-221 is also involved in liver cancer. Ogawa et al. first showed that miR-221/222 expression was upregulated in HCV-infected patients and patients with NASH dependent on the progression of liver fibrosis and that it closely correlated with the mRNA expression of collagen 1 A1 and α-SMA. Upregulation of miR-221/222 expression was also confirmed in a mouse liver fibrosis model induced by thioacetamide. MicroRNA-221/222 expression increased during HSC activation, and it regulated cyclin-dependent kinase 1B expression. 65 Shen et al. reported the modulation of liver fibrosis by miR-222 in a mouse model of biliary atresia. 66 Dong et al. identified that protein phosphatase 2 A subunit B was a target of miR-222. 67 
Others
Du et al. recently reported that miR-146-5p played a role in HSC activation through the targeting of Wnt1 and Wnt5a in a mouse model of non-alcoholic fibrosing steatohepatitis. 68 Povero et al. showed that the presence of miR-128-3p in extracellular vesicles derived from fatladen hepatocytes targeted PPAR-γ and promoted profibrogenic gene expression, such as collagen 1, α-SMA, and TIMP-2. 69 Therefore, miRNAs are also implicated in fibrosis development in NASH.
MICRORNAS AS BIOMARKERS FOR LIVER PATHOPHYSIOLOGY
L IVER BIOPSY IS the gold standard for the diagnosis of the etiology of liver diseases, liver inflammation, liver fibrosis, and liver cancer, but non-invasive methodologies are being developed using serum markers and imaging technologies. The successful recent progression in the field of liver fibrosis diagnosis is the result of the development of useful fibrosis scores, such as AST to Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4), FibroTest, and FibroMeter, and ultrasound and magnetic resonance imaging-based measurements of liver stiffness. 70 However, the diagnostic markers of HCC have remained unchanged, including the use of α-fetoprotein and des-γ-carboxy prothrombin in the serum and the detection of the space occupying lesions by using ultrasound, computed tomography, and magnetic resonance-based imaging. Nevertheless, efforts have been made to establish a specific, repetitive, and easy method for diagnosing liver disease using circulating miRNAs.
Hepatocellular carcinoma
Li et al. first indicated the utility of the combination of miR-25, miR-375, and let-7f as a biomarker to separate HBV-derived HCC from controls (area under the curve, 99.67 ± 0.15%; sensitivity, 97.9%; specificity, 99.1%). 71 Circulating miR-141 and miR-200a were significantly downregulated in HCC patients compared with patients with liver cirrhosis (P < 0.007) and healthy controls (P < 0.002) in a recent report. 72 Lin et al. showed the utility of an miRNA classifier containing miR-29a, miR-29c, miR133a, miR-143, miR-145, miR-192, and miR-505 in identifying small-sized, early-stage, and α-fetoprotein-negative HCC derived from HBV-infected patients. 73 Wen et al. indicated four miRNAs, including miR-20a-5p, miR-320a, miR-324-3p, and miR-375, in addition to serum α-fetoprotein levels, as potential preclinical biomarkers of HBV-derived HCC. 74 These and other reports indicate that miRNAs may be biomarkers for the detection of HCC, but candidate miRNAs are different across the cohorts studied.
Further research using larger patient cohorts and several etiologies are definitely required in future works.
Non-alcoholic steatohepatitis
Four independent groups reported the use of serum miR-122 level as a biomarker for NAFLD and NASH. Miyaaki et al. reported a significant correlation of serum miR-122 levels with hepatic miR-122 expression in NAFLD patients and an inverse correlation of serum miR-122 levels with hepatic fibrosis. 75 Pirola et al. identified an increase in miR-122 (7.2-fold change in NASH compared with control) and miR-192 (4.4-fold change in NASH compared with control) among 84 circulating miRNAs tested and the overexpression of miR-122 in lipid-laden hepatocytes using in situ hybridization. 76 Similar observations were reported by Becker on the utility of serum miR-122, miR-192, and miR-21 77 and Tan using a serum miRNA panel (miR-122-5p, miR-1290, miR-27b-3p, and miR-192-5p) for the diagnosis of NAFLD. 78 
Autoimmune hepatitis and PBC
Circulating miRNA profiles were examined in type-1 autoimmune hepatitis patients, and an increase in miR-21 and miR-122 was reported in these patients compared with healthy controls. Reductions in miR-21 and miR-122 were observed in patients treated with corticosteroids and patients with advanced liver fibrosis. 79 Primary biliary cholangitis patients are diagnosed using a serum miRNA panel consisting of miR-122-5p, miR-141-3p, and miR26b-5p with high accuracy (sensitivity, 80.5%; specificity, 88.3%). The sensitivity and specificity of this panel was less than the serum levels of an antimitochondrial antibody, but these values were higher than the serum levels of an antinuclear antibody and alkaline phosphatase. 78 Ninomiya et al. reported a unique miRNA expression pattern in the sera of PBC patients, and PBC patients were distinguished from a viral hepatitis group by the downregulation of miR-505-3p, miR-139-5p, and miR-197-3p expression. 80 
FUTURE THERAPY FOR LIVER DISEASE USING MIRNAS
M ICRORNAS CAN BE possible candidates for future therapies targeting liver disease. Several trials have recently been reported regarding the possibility of liver fibrosis treatment with miRNA. MicroRNA-214 participated in the development of hepatic fibrosis by modulating the epidermal growth factor receptor and TGF-β signaling pathways. By using platelet-derived growth factor-c transgenic mouse, LNA-anti-miR-214 showed the preventive effect for hepatic fibrosis. 81 Inhibition of miR-21 also reduced liver fibrosis through concomitant reduction of CD24 + liver progenitor cell and S100 A4 + cancer-associated stromal cells. 82 Novel nucleic acid therapies for cancer have also emerged as potential clinical applications. MicroRNA34a, 83 let-7, 84 and miR-16 85 have been well documented as tumor suppressor miRNA. MicroRNA-34 is a representative tumor suppressor miRNA acting through the p53 pathway. 86 Mirna Therapeutics (Austin, TX, USA) has been promoting the development of MRX34, which is a custom nanoparticle liposome containing a miR-34a mimic compound. Application of MRX34 for several mouse cancer models, including prostate cancer 87 and lung cancer, 88 was carried out preclinically. Moreover, according to the promising result using a mouse HCC model, Mirna Therapeutics is progressing the clinical trial for non-resectable HCC and metastatic liver tumor. In addition, cholesterol conjugated let-7a mimics showed downregulation of the Ras gene, resulting in antitumor function on a hepatoma cell line and orthotopic xenograft model. 89 
CONCLUSION
M
ICRORNAS CONTRIBUTE TO the pathogenesis of liver disease of any etiology and regulate the expression of multiple genes that control inflammation, fibrosis, and cancer development. MicroRNA-122 is most abundant in hepatocytes and primarily regulates their metabolism, but multiple miRNAs also modify the functions of other hepatic constituent cells. Circulating miRNAs in the serum also reflect pathological conditions of the liver and may serve as plausible and non-invasive biomarkers for the diagnosis of the etiology and progression rate of liver disease.
